From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from a recent survey of a critical mass of diagnostic labs in the U.S, with analysis from Kalorama’s leading diagnostic analyst, Shara Rosen.

Far more than any other market research report, this report provides the most current and accurate picture of what is truly going on in molecular diagnostics in the United States.

Quantitative Data

Analyzed by the best-selling author of The Worldwide Market for In Vitro Diagnostics, now in its sixth edition, this new report includes surveys of molecular diagnostics focusing on these tests:

• Chlamydia and Gonorrhea
• HBV Viral Load
• HCV Viral Load, HCV Genotyping
• HIV Viral Load, HIV Genotyping
• HPV, HPV Genotyping
• Hospital Acquired Infections – MRSA, VRE
• Coagulation Factors – Factor II, Factor V Leiden
• Herpes Simplex Virus (HSV)
• Oncology Tests – BCR/ABL, Bladder Cancer, Her2Neu, MTHFR
• Transplant Medicine – HLA Typing
• Hereditary Disorders – Cystic Fibrosis (CF), Fragile X
• Respiratory Infections – Influenza A/B, Group A Strep, MTB (Tuberculosis), Bordetella pertussis, Adenovirus, Respiratory Virus
• Communicable Diseases – CMV (Cytomegalovirus), EBV (Epstein-Barr Virus), Group B Strep, Enterovirus

What Labs Do Now, What They are Planning in the Future

There has been much analysis in recent years about the inroads that DNA testing has made. This unique resource offers a way to measure that progress, and test assumptions aobut the evolution of DNA testing, critical information to adjust business stratetgies. This report looks at the following topics:

• What type of reagents are labs using (Commercial, ASR, Homebrew)
• Where tests are performed (Central/Core Testing Lab, Chemistry Lab, Cytology Lab, Genetics Lab, Hematology Lab, Microbiology Lab, Molecular Lab, Pathology Lab, Serology/Immunology Lab, Virology Lab)
• What Vendors are Labs Using
• What are there Purchasing Plans
• What Tests Do They Want in the Future
• Do They Outsource and at what Rate?
• Do They plan Vendor Changes?

A Representative Sample of the US Hospital Lab Industry

Emmes Group reached an extensive sample group – interviewing 14% of US hospital labs, 14% of public labs and 8% of US reference lab, where Emmes respondent numbers are compared to the Americian Hospital Directory. Such an undertaking would cost an individual company tens of thousands of dollars. This information is available to purchasers of this report at a fraction of the cost.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1631/Who-s-Doing-What-in-Molecular-Diagnostics-Kalorama-Emmes-Survey-of-US-Laboratories.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Molecular diagnostics represents a revolution postponed, perhaps, but one that is now clearly underway. DNA Testing has emerged fully from research into clinical practice and becoming a dominant platform in clinical medicine.

From Emerging to Emergent Technology

Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. At each step of the way, Kalorama Information has reported on its progress, and in this latest market research report we look at the present state of the market, and the advances that have made DNA testing routine.

Many molecular tests are CE Marked and FDA-cleared and many more are in development. The result is that molecular testing is indicated in many areas of health care.

Molecular Testing Compiled and Analyzed and Explained by a Leading Expert

Authored by lead Kalorama diagnostic analyst Shara Rosen, Kalorama Information’s World Market for Molecular Diagnostics is the most comprehensive global market report available on the emergent field of molecular diagnostics.

This report covers key platforms of molecular diagnostics, including the following :

• Polymerase Chain Reaction (PCR)
• Non-PCR Amplification Technologies, including:
  • bDNA
  • TMA
  • SDA
  • LIPA
  • NASBA
  • Invader
  • Others
• In-situ Hybridization
• Sequencing
• Microarrays
• Laser Capture Microdissection (LCM) and Tissue Arrays
• Mass Spectroscopy
• Other Molecular Platforms

This report provides market estimates and analysis for molecular diagnostics in the following categories:

• Infectious Diseases (including HIV, Hepatitis GC/Chlamydia,Organism ID, MRSA, HAI et al, Mycobacteria, TB Respiratory, Others)
• Blood Screening
• Histology
• Oncology
• Prenatal
• Coagulation
• Tissue Typing
• Inherited Diseases
• Pharmacodiagnostics

The various clinical techniques and trends are discussed from the point of view of their present and potential market impact.

Market analysis in this report covers world markets for in vitro diagnostics, with focus on the developed areas of the globe — North America and Western Europe. However public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases.

As part of its exhaustive coverage of nucleic acid testing, the report includes the following:

• Market Sizes and Forecasts
• Profile and Assessment of Over 140 Key Competitors
• Breakout of Molecular Diagnostic Market by Region (N. America, W. Europe, Asia, ROW)
• Medical and Technological Trends
• Discussion of Globalization of Markets and Diseases
• Information on Reimbursement of New Technologies
• Review of Novel Test Platforms
• Review of New Market Developments, Such as Consumer Genomics and Testing Services
• Discussion of Market Impact of Home Brew Tests
• Discussion of Diagnostic Biomarkers and Genetic Indicators

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Data for the molecular test market are presented in U.S. dollar market size for categories of tests, and for specific analytes where possible. The dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.

The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and techniques presented in the report are expected to replace the standard of care in 2007/08, but with healthcare systems’ emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1621/The-World-Market-for-Molecular-Diagnostics.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

This Kalorama Information report – Clinical Nutrition – focuses on three primary segments of essential medical nutrition:

• Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort)
• Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients)
• Parenteral Nutrition

For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall global population. Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets. The market segments provide an overview, description of products on the market, new developments, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

Coverage of Issues and Trends in Clinical Nutrition

There are several issues and trends that are impacting the clinical nutrition market, including:

• Wound Care Applications
• Reimbursement of Nutrition Products
• Food Programs
• Nutrition and Education
• DHA and ANA Additives
• Counterfeit Infant Formulas
• Recalled Infant Formulas
• Acquisition, Mergers and Alliances
• Technology Applications

A Growing Market with Thriving Competition

Competition in the clinical nutrition market is dominated by a handful of companies, ranging from global nutritional manufacturers to leading pharmaceutical companies. The majority of competitive participation is in developed regions such as the United States, Western Europe, and Japan. However, many companies are expanding into less developed regions, intensifying competition in less tapped markets. China, for example, is among the expanding competitive regions as companies continue to break into the growing demand for clinical nutrition in new world markets. Companies highlighted in this study include:

• Abbott Laboratories
• Baxter International
• B. Braun
• Danone
• Fresenius Kabi
• Mead Johnson
• Nestle
• PBM Products
• Wyeth

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study, Kalorama Information conducted interviews with more than 80 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with nutrition company representatives included marketing directors, division managers, and product representatives. All market data pertains to the world market at the manufacturers’ level.

The base year for data was 2008. Historical data was provided for the years 2006 and 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2006-2008, 2008-2013 and 2006-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on demographic trends, new developments, and global expansion.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1626/Clinical-Nutrition-Products-World-Markets-3rd-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions.

This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2008 period and forecasts are provided through 2013.

Since the last edition of this report:

• Vaccine makers are now advertising directly to the public with growing DTC budgets. The report identifies the possible market impact of this new trend.
• The economy has impacted vaccine sales with more people unable to make required out of pocket payments for vaccination.
• New categories of vaccines, such as allergy vaccines, are becoming more prominent, and have been included in our forecasts.
• Several major new products, including Wyeth’s Prevnar 13, are on the horizon. The market impact of new products is discussed.
• Two major mergers – Pfizer/Wyeth and Merck/Schering-Plough, will impact the industry and this is considered in our market analysis.

Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2008. Since Kalorama Information last updated Kalorama Information’s The World Market for Vaccines last year, new products and better than expected profits have transformed the vaccine marketplace. Continued sales of influenza vaccines and cervical cancer vaccines have provided a foundation for growth in the adult market. The competitive dynamics have changed with mergers, and many new products are on the way.

Kalorama Information’s exhaustive research and analysis built from interviews with key decision makers in the market includes the following:

• Review of Products in the Market
• Current World Market Size for Pediatric and Adult Vaccines
• Segmented Revenues and Forecasts to 2013 by Category
• Over 45 Charts and Tables To Make Information Accessible
• Discussion of The Current Economy and Vaccines, Immunization Refusal, Swine/Avian Flu and Other Pandemics, Delivery Sys and other Trends in the Vaccine Market
• Important Vaccines and Immunization Schedules and Statistics
• Profiles of 15 Key Vaccine Companies
• Thorough Review of the Vaccine Pipeline and Possible Impact of New Products

Who are the main players in the vaccine market? What opportunities are available for pharmaceutical companies or investors from this market? What are the potential challenges vaccine competitors must deal with? What will be the impact of the first successful cancer product? What is the significance of at least one major acquisition to affect this industry? These questions and more are tackled in this report.

Current revenues and revenue forecasts to 2013 are included for the following pediatric vaccine categories:

• DTaP & DTP Vaccines
• Hep Vaccines
• HiB Vaccines
• MMR Vaccines
• Combination Vaccines
• Pneumococcal Vaccines
• Polio Vaccines
• Varicella Vaccines
• Other Pediatric Vaccines

As well as Revenues and Forecasts to 2012 for the following adult vaccine categories:

• Influenza Vaccines
• Hepatitis Vaccines
• Pneumococcal Vaccines
• Travel, DT and other Adult Vaccines
• Cervical Cancer

This is a rapidly changing marketplace and knowledge of the R&D pipeline is essential to truly understand what is happening in vaccines. Vaccines in development are discussed in this report, including vaccines for the following conditions:

• Enterotoxigenic Escherichia coli
• Parainfluenza Virus Type 3
• Pneumococcal Vaccines
• Respiratory Syncytial Virus<
• Cancers
• Cholera
• HIV/AIDS
• Helicobacter Pylori
• Malaria
• Rabies
• Tuberculosis
• West Nile Virus

This Kalorama Information report was created with a primary research effort. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1645/Vaccines-2009-World-Market-Analysis-Key-Players-and-Critical-Trends-in-a-Fast-Changing-Industry.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

As Kalorama Information’s lead diagnostic analyst finds, the point of care concept is at a crossroads: the technologies needed to make rapid testing a reality have arrived. But is healthcare ready?

Kalorama believes that the drive for wellness and the attention surrounding healthcare reform will focus attention on rapid diagnostics. However, according to Shara Rosen, RT, M.B.A., there are many challenges which must be overcome for point of care solutions to be fully utilized, and those companies willing to pivot strategies and best adjust to tomorrow’s healthcare marketplace may be rewarded.

This report, Point of Care Diagnostics 2010: Rapid Testing at a Crossroads represents the most current analysis of the role POC Diagnostics in today’s in vitro industry. Other reports have looked at products, companies and revenue numbers, as this report does. But in her analysis Shara Rosen takes a bold look into the markets, technologies, and trends in decentralized testing with a special focus on the economics of rapid test use in critical care and emergency medicine. The report includes:

• Markets for POC Diagnostics (Diabetes, Cardiac markers, Clinical Chemistry/Critical Care, Hematology, Coagulation, Drugs of Abuse/Therapeutic Drug Monitoring, Infectious Diseases, Pharmacodiagnostics, Sepsis, Oncology, Women’s health / Pregnancy/Fertility)
• By Venue Revenue Estimates for Hospital POC, Physician POC and Other Venue
• Review of Products in the Market
• Forecasts to 2013
• Markets and Forecasts for Self-Testing (OTC)
• The role of EMR in the Point of Care Market
• Possible Effects of Healthcare Reform
• POLs, Home Monitoring, Alternate Samples and Other Trends
• Successful Strategies of POC Companies
• Profiles of Over 100 Companies Competing in this Market

There are many factors in the growth of POC testing- increasing numbers of diagnosed diabetics, people with cardiovascular disease, and other chronic conditions. It is also expected to play a role in a trend in health care to evaluate provider organizations for quality in care delivery. While this quality imperative is most apparent in pay-for-performance systems, it also provides a framework by which public funds can be used more rationally. This is an especially relevant technology given the U.S. healthcare reform efforts.

All countries are feeling the brunt of aging populations and an increased burden of chronic disease management. Employers and insurance companies are interested in improving the health of customers, and there are some innovative tactics developing in this area. The report is conservative in its predictions and offers a calculated look into the future, based on events currently taking place.

The report offers a quantitative assessment of specific markets in US dollars for 2008 and forecasted out to 2013. These data are provided in order to set the status quo of tests and technologies. However the report concentrates on how these will impact the economics of healthcare over the near term and longer when possible.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1660/Point-of-Care-Diagnostics-2010-and-Beyond-Rapid-Testing-at-a-Crossroads.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? This Kalorama Information report What’s Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched, including the following target areas:

• Addiction
• Allergy
• Alzheimer’s Disease
• Anthrax
• Asthma
• Campylobacter Infection
• Chlamydia
• Croup
• Dengue Fever
• Diabetes
• Ebola
• Epstein-Barr Virus
• Enterotoxigenic Escherichia coli
• Helicobacter Pylori
• Hepatitis
• Herpesvirus
• Hookworm
• Hypertension
• HIV/AIDS
• Leishmaniasis
• Malaria
• MRSA Infection
• Multiple Sclerosis
• Obesity
• Parainfluenza Virus Type 3
• Parkinson’s Disease
• Plague
• Respiratory Syncytial Virus
• Ross River Virus
• Shigellosis
• Smoking
• Stroke
• Tuberculosis
• West Nile Virus

Some of these vaccines may see success; some could be the blockbusters of the future. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Alison Sahoo has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.

There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies

• Acambis plc
• ACE BioSciences
• AFFiRiS
• ALK-Abello A/S
• Allergy Therapeutics
• Bavarian Nordic A/S
• Baxter Healthcare
• Celldex Therapeutics
• Crucell
• Cytos Biotechnology
• GlaxoSmithKline
• Hawaii Biotech
• Intercell
• Medimmune
• Merck & Co. Inc
• Mymetics
• Nabi Biopharmaceuticals
• Novartis
• Opexa Therapeutics
• Paladin Labs
• Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2020. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.

Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1594/What-s-Next-in-Vaccines-HIV-Malaria-Rabies-MRSA-and-30-Other-Vaccine-Targets-in-the-2010-2020-Pipeline.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.

These changes and more are addressed in Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:

• Histology/Cytology
• Immunoassays
• Flow Cytometry
• Rapid Tests
• Molecular Assays
• Tissue Arrays
• Circulating Tumor Cells
• Pharmacodiagnostics

Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:

• Immunoassay Lab Based Cancer Test Sales
• Pap Smear Testing Volumes
• World Cancer Statistics
• POC Tests
• DNA Reagents for Cancer Testing
• CTC Testing Markets
• Biochip Innovations
• New Companies with Novel Approaches
• “Laggard” Companies Who Have Not Met Expectations
• Major Protein and Molecular Markers Used in Tissue Staining
• Biomarkers Under Investigation
• Acquisitions and Mergers
• Status of PGx Testing
• Microarray Markets in Clinical Labs
• Lists of Vendors and Major Products
• Unmet Needs of the Marketplace

This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH As well as tests for specific cancers:

• Bladder Cancer
• Breast Cancer
• Cervical Cancer
• Colon Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer

This latest edition of Kalorama Information’s study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:

• Tests for specific cancers, and
• Cancer tests in specific IVD segments

This allows the reader to match his or her own situation to the market at large.

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles.

Top Tier Companies

• Abbott Diagnostics
• Beckman Coulter Inc.
• Becton, Dickinson and Company (BD)
• bioMerieux Inc.
• Bio-Rad Laboratories Inc.
• Dako A/S
• Fujirebio Diagnostics, Inc.
• Gen-Probe Inc.
• Hologic, Inc.
• Inverness Medical Innovations
• Ortho Clinical Diagnostics
• QIAGEN N.V.
• Roche Diagnostics
• Siemens Medical Solutions Diagnostics
• Sysmex Corporation

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/2216/The-Worldwide-Market-for-Cancer-Diagnostics-4th-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Kalorama Information publishes its third edition of this detailed report on the long term care industry at a time of growth but also change and concern for the long term care industry. The economy has challenged the business strategies of key players, while the recent healthcare legislation introduces changes that may affect revenues. These twin challenges are addressed in The Long-Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living The report provides an in-depth examination of the market for long-term care today. The following segments are broken out in detail: This report covers the most important segments of the long term care industry, each of which provide medical care and/or assistance with the activities of daily living (ADLs) on an ongoing basis:

• Nursing care;
• Home Care;
• Hospice Care;
• Assisted Living.

Excluded are markets that address temporary care needs such as physical or mental rehabilitation. Residential living programs and facilities that do not generally provide care such as retirement communities.

For each of the segments of long term care the report provides:

• Market Size and Forecast
• Number of Facilities/Providers and Growth Trends
• Patient Statistics
• Forms of Payment and Reimbursement Levels
• Trends Affecting the Marketplace
• Competitors and Competitive Analysis

Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are provided for the historic 2005 to 2009 period and forecasts are provided through 2015.

As part of the report’s analysis of the state of the industry, the report covers the Recent Healthcare Reform and its Impact on Nursing Homes and the Effects of the Economy Other issues and trends discussed in the report include:

• Medicare & Health Care Reform
• Patient Dumping
• Quality of Care
• Federal Quality Improvement Initiatives
• State Quality Improvement Initiatives
• Legal Actions
• Safety
• Aging of the Population
• Marital and Living Arrangements
• Geographic Concentrations
• Certification and Accreditation
• Fees and Payment
• Long Term Care Insurance
• Cost of Coverage and Affordability
• Staffing and Human Resources
• Building of New Facilities

Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

As part of its coverage of the industry, the following long term care companies were profiled in this report:

• Apria Healthcare Group Inc./ Blackstone Group
• Brookdale Senior Living
• Emeritus Corporation
• Extendicare, Inc.
• Genesis Healthcare
• Golden Living
• Manor Care, Inc.
• Sun Healthcare Group Inc.
• Sunrise Senior Living Inc.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/3346/Long-Term-Care-Market-Nursing-Homes-Home-Care-Hospice-Care-and-Assisted-Living.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

In seven best-selling editions, Shara Rosen has provided a total view of every aspect of the market for in vitro diagnostic (IVD) testing in one complete volume. The report, The Worldwide Market for In Vitro Diagnostic Tests, stands as a testament to the Kalorama methodology. Real industry knowledge combined with an exhaustive review of the medical, business, and company literature. Market numbers for business planning matched with a discovery of the trends that are impacting the industry. A realistic forecast five years into the future for companies already participating in or considering entry into this growing industry. The idea behind Kalorama’s unique report is that the entire market can be captured in one volume and business planners can use it as a key reference. Published every two years, this volume includes coverage of the most important aspects of all of the major segments of clinical lab testing, including:

• Point of Care (POC), (Professional and Self-Testing)
• Core Lab (General Chemistries, Workstations, Analyzers)
• Immunoassays (Blood Gases, Urinalysis, Critical Care)
• Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
• Hematology
• Coagulation (Lab-Based, POC, Genetic Markers)
• Microbiology and Virology
• Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
• Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV)

For each of these sections, Shara Rosen reviews the key products dominating the market segment, the innovations that are occurring, trends that are impacting the segment. Market size, and forecast and market share are provided; and discussion of regional numbers of the segment is provided where possible. Changes in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Current market is provided for 2009; projections are made through 2014.

Kalorama Information’s Report – ‘The Bible of the IVD Industry’

Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. These are the numbers that it is very likely competitive companies will be using in their planning.

This 900+ page edition greatly expands coverage of the field and tracks the most important developments.

A Global Report

IVD is a worldwide business. While the US is a large healthcare market, much of the dynamism occurs in other areas. Many of the most interesting developments are occurring in emerging markets. As part of its coverage, the report breaks down the entire IVD market for the following regions.

• North America
• Europe (EU)
• Eastern Europe
• South America
• Asia (China and India as subsegments)
• Rest of World

A Report Designed for a Changing Industry

In this seventh edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama Information has reorganized the presentation of the IVD market in a manner that better reflects how the industry has evolved.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/6013/The-Worldwide-Market-for-In-Vitro-Diagnostic-Tests-7th-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

This new Directory combines both the whole database of the European Pharmaceutical Directory 2010 and the USA Pharmaceutical Directory 2009 into one set of books and onto one set of CD-ROMs.

http://www.visionshopsters.com/product/1196/The-European-Pharmaceutical-Directory-2010-and-The-USA-Pharmaceutical-Directory-2010.html

The European & USA Pharmaceutical Directory 2010 has been thoroughly researched, to bring you a completely up-to-date guide to Europe’s & America’s ever-changing pharmaceutical industries.

If you sell or buy Pharmaceuticals, Biotechnology products, Biopharmaceuticals, Bulk Pharmaceuticals, OTC/Healthcare products, Fine Chemicals, Generics, Genomics, or Diagnostics/Reagents; or, if you’re looking to break into this appealing market, the new European & USA Pharmaceutical Directory 2010 will provide you with thousands of fresh business contacts – and help you keep track of old ones – quickly and easily.

This new directory covers the entire European & USA pharmaceutical & biotechnology industry sector including

• Pharmaceuticals; Biotechnology; Biopharmaceuticals; Bulk Pharmaceuticals; Drug Delivery
• OTC/Healthcare Products; Clinical Research; Research & Development
• Ethical Pharmaceuticals; Fine Chemicals; Generics; Genomics; Contract Manufacturers
• Contract Research; Cosmetics; Diagnostics/Reagents; Licensing
• Plus 30 more categories!

DATABASE 1: The European Pharmaceutical Directory 2010

Whether you are a product manager, in charge of marketing or simply interested to remain in touch with the latest developments in the European pharmaceutical industry, this Directory will save you time and effort in finding the up-to-date information you need.
The European Pharmaceutical Directory 2010 gives you instant access to a wealth of accurate contact information on over 4,500 companies in Austria, Belarus, Belgium, Bosnia, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia, the Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Ukraine, and the United Kingdom. This essential Directory is your connection to key decision-makers in the pharmaceutical industry in Europe.

DATABASE 2: The USA Pharmaceutical Directory 2010

The USA Pharmaceutical Directory 2010 is one of the most comprehensive and accurate Directory of companies and executives in the USA pharmaceutical industry that have ever been published. It contains more than 3,000 pharmaceutical companies and 7,000 executives working in the industry in the USA. This powerful Directory is your connection to key decision-makers in the pharmaceutical industry in the Americas.
Whether you are a product manager, in charge of marketing or simply interested to remain in touch with the latest developments in the pharmaceutical industry, this Directory will save you time and effort in finding the information you need.
Listing over 7,500 companies, entries in The European & USA Pharmaceutical Directory 2010 feature:
Full company contact details including telephone and fax
Web and email addresses
Names of key management and trading personnel
Locations of offices
Main product information
Number of Employees

This combined Directory will enable you to:

• Profile a market
• Build new business prospects
• Pinpoint key executives
• Generate new customers
• Discover who your competitors are
• Make vital contacts
• Save the time, money and effort of doing your own research
• Identify alternative suppliers and manufacturers
• Source up-to-date company information
• Access a wealth of quality information on healthcare companies

6 Great Reasons to order your copy of The European & USA Pharmaceutical Directory 2010

1. Save time: no need to search the internet, all the information you need is in one handy guide;
2. Save money: by using a resourceful book that details all your business contacts activities;
3. Gain an understanding of the key players in this increasingly dominant market: quickly and easily
4. Source the right trader/producer: by identifying products quickly;
5. Discover new business leads: and grow your business;
6. Update your contact list: from the most reliable source in the industry.

This combined Directory is truly an indispensable guide to the European & American pharmaceutical companies and key pharmaceutical decision makers!

Why wait? If you’re are buying or selling pharmaceuticals into the European or American market, or wishing to do so, this directory is essential for you. Where else will you find such a broad depth of both key contact and production information for the European & American pharmaceutical industry in one handy reference source?

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1196/The-European-Pharmaceutical-Directory-2010-and-The-USA-Pharmaceutical-Directory-2010.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com